Metsera, Inc. (MTSR)’s MET-233i Shows 8% Weight Loss in Phase 1

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Metsera, Inc. is one of them.

Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biotech based in New York, is emerging as an innovative player in obesity and metabolic disease treatments. The company develops next-generation injectable and oral hormone analog peptides designed for potency, scalability, and improved patient adherence.

In 2025, Metsera, Inc. (NASDAQ:MTSR)’s lead candidate, MET-233i, an ultra-long-acting amylin analog, showed promising Phase 1 results, with patients achieving up to 8% body weight reduction over five weeks. Its extended half-life supports once-monthly dosing, offering greater convenience and potential compliance benefits compared to existing therapies. MET-233i is being developed both as a standalone treatment and in combination with other obesity medicines in the business’s pipeline.

Metsera, Inc. (MTSR)’s MET-233i Shows 8% Weight Loss in Phase 1

Another key asset, the GLP-1 receptor agonist MET-097i, is progressing through multiple Phase 2b trials, with data readouts expected later in 2025 and Phase 3 trials planned to begin by year-end. The corporation is preparing to present these results at upcoming medical and investor conferences, signaling growing scientific and market interest.

While we acknowledge the risk and potential of MTSR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MTSR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.